SecBot SecBot
PRESS-RELEASE ·Filed May 18, 2026

TEVA

Teva Pharmaceutical Industries Ltd
NEUTRAL
Impact 3/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This press release is a routine clinical data presentation with no immediate financial or regulatory catalyst for Teva. Traders should monitor for any future regulatory actions or label expansions related to TD treatments, but no near-term stock-moving event is indicated.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$34.03
T+0 close · May 18, 2026 · via day close
Latest settled
+7.67%
T+60 · $36.64
Vs SPY
+3.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $34.03entry
  2. T+1 · 6mo ago +0.13%α +0.78% · $34.07
  3. T+5 · 6mo ago +1.70%α +0.09% · $34.61
  4. T+20 · 5mo ago −0.99%α −3.18% · $33.69
  5. T+60 · 3mo ago +7.67%α +3.09% · $36.64

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teva presented new IMPACT-TD Registry data at the 2026 APA Annual Meeting, revealing that 85% of young adults (18-29) with mood disorders and tardive dyskinesia experience moderate-to-severe impact, yet only 23% received a formal diagnosis. The data highlights a significant diagnostic gap and underscores Teva's commitment to TD research, but the press release contains no financial figures, no regulatory decision, and no change to Teva's commercial outlook.

Key Facts

  • New IMPACT-TD Registry data presented at APA 2026 shows 85% of young adults (18-29) with mood disorders and TD experience moderate-to-severe impact.
  • Only 23% of young adults (18-29) with TD received a formal diagnosis, revealing a diagnostic gap.
  • Average delay in TD diagnosis is more than 3.5 years after involuntary movements are first recognized.
  • The IMPACT-TD Registry is a 3-year, prospective, Phase 4 study with 611 participants.
  • No financial data, revenue figures, or changes to Teva's product pipeline were disclosed in the press release.

Financial Impact

No financial impact disclosed; the press release is a clinical data update with no revenue or earnings implications.

Risk Factors

  • No new commercial or regulatory catalyst; the data does not change Teva's near-term revenue or earnings outlook.
  • Diagnostic gap findings may not translate into increased prescribing or market share for Teva's TD treatments.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3296535

Track record

61 reports on TEVA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens Wed (11h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026